INmune Bio Shows Alzheimer's Signal in Subgroup, Advances RDEB Therapy
Event summary
- INmune Bio reported clinical learnings from its Phase 2 Alzheimer’s disease trial (MINDFuL), showing a treatment effect in a predefined subgroup of amyloid-positive patients with neuroinflammation.
- The company is advancing CORDStrom™ for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with pilot-scale manufacturing runs completed and plans for a Marketing Authorization Application (MAA) submission to the UK’s MHRA in mid-summer 2026.
- As of September 30, 2025, INmune Bio held approximately $27.7 million in cash and cash equivalents, sufficient to fund operations through year-end 2026.
- A peer-reviewed study published in December 2025 highlighted the therapeutic potential of CORDStrom™.
The big picture
INmune Bio's strategy of targeting neuroinflammation in Alzheimer's disease represents a shift towards precision medicine approaches, aligning with evolving regulatory expectations and payer demands. The company's focus on rare diseases like RDEB, while niche, offers a potential pathway to accelerated approval and market exclusivity. The observed signal in the MINDFuL trial, while limited to a subgroup, provides a potential foothold in a market dominated by larger competitors like Biogen.
What we're watching
- Regulatory Risk
- The success of CORDStrom™ hinges on timely regulatory approvals from the MHRA and FDA, and any delays in the MAA or BLA submissions could significantly impact the company's timeline and valuation.
- Clinical Validation
- Whether INmune Bio can replicate the observed Alzheimer’s signal in a larger, registration-quality trial will be critical to validating the XPro™ program and attracting further investment.
- Manufacturing Scale
- The ability to consistently manufacture CORDStrom™ at commercial scale, as demonstrated by the CGT Catapult pilot runs, will be essential for meeting potential demand and achieving regulatory approval.
Related topics